A New Microemulsion Formulation of Cyclosporin: Pharmacokinetic and Clinical Features

Clinical Pharmacokinetics

Volumn 30, Issue 3, 1996, Pages 181-193

  Friman, Styrbjörn ^a   Bäckman, Lars ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

AREA UNDER THE CURVE; BILE; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; EMULSION; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MICELLE; ORGAN TRANSPLANTATION; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SMALL INTESTINE ABSORPTION;

CYCLOSPORINE; DRUG COMPOUNDING; EMULSIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION;

EID: 0029930431     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630030-00001     Document Type: Article

References (50)

1. Calne RY, White DJG, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; II: 1323-7
2. McMaster P, Dunn DC, Craddock GN, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs; 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; II: 1033-6
3. Starz TE, Weil R III, Iwatsuki S, et al. The use of cyclosporin A and prednisone in cadaveric kidney transplantation. Surg Gynecol Obstetr 1980; 151: 17-26
4. Klintmalm GBG, Iwatsuki S, Starzl TE. Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet 1981; 1: 470-1
5. Powles RJ, Clink HM, Spence D. Cyclosporin A to prevent graft-versus-host disease in man after allogenic bone-marrow transplantation. Lancet 1980; 13: 365-7
6. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporin improves psoriasis in a doubleblind study. JAMA 1986; 256: 3110-6
7. Tugwell P, Bombardier C, Gent G, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 1051-5
8. Feutren G, Mihatsch MJ, the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. Risk factors for cyclosporine-induced nephropathy in patients with autoimmundiseases. New Engl J Med 1992; 326: 1654-60
9. Mehta M, Venkataramanan R, Buckart GJ. Effects of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol 1984; 25 (5): 579-84
10. Vonderscher J, Meinzer A. Rationale for the development of Sandimmun Neoral. Transplant Proc 1994; 26: 2925-7
11. Drewe J, Berglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992; 33: 39-43
12. Friman S, Persson H, Karlberg I, et al. The bile acid independent flow is reduced in the transplanted liver. Transplant Int 1992; 5: S163-S167
13. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-18
14. Ritschel WA, Adolph S, Ritschel GB, et al. Improvement of peroral absorption of cyclosporin A by microemulsions. Meth Find Exp Clin Pharmacol 1990; 12: 127-34
15. Levy G, Grant D. Potential for CsA-Neoral in organ transplantation. Transplant Proc 1994; 26: 2932-4
16. Lin CY, Lee SF. Comparison of pharmacokinetics between CsA capsules and in Sandimmun neoral in pediatric patients. Transplant Proc 1994; 26: 2973-4
17. Superina RA, Strong DK, Acal LA. Relative bioavailability of Sandimmune and Sandimmune Neoral in pediatric liver recipients. Transplant Proc 1994; 26: 2979-80
18. Vernillet L, Kovarik JM, Freiburghaus R. Blood cyclosporin A and metabolite kinetic profiles after administration of Sandimmune soft gelatine capsules and Neoral in transplant recipients. Transplant Proc 1994; 26: 2964-8
19. Trull AK, Tan KKC, Tan L, et al. Absorption of cyclosporin conventional and new microemulsion formulations, in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol 1995; 39: 627-31
20. Drewe J, Meier R, Vonderscher J, et al. Enhancement of the absorption of cyclosporin in man. Br J Clin Pharmacol 1992; 34 (1): 60-4
21. Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from microemulsion formation. Pharm Res 1994; 11: 301-4
22. Mueller EA, Kovarik JM, van Bree JB, et al. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporin in a crossover comparison with the market formulation. Pharm Res 1994; 11: 151-5
23. Browne BJ, Jordan MS, van Buren C, et al. Diet and cyclosporin A - pharmacokinetic comparison between Neoral and Sandimmune gelatin capsules. Transplant Proc 1994; 26: 2959-60
24. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formation - a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658-63
25. Kahan BD, Dunn J, Fitts C, et al. The neoral formulation: improved correlation between cyclosporine trough concentrations and exposure in stable renal transplant recipients. Transplant Proc 1994; 26: 2940-3
26. Mueller EA, Kovarik JM, van Bree JB, et al. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients - a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57: 1178-82
27. Foradori AC, Martinez, L, Vacarezza A, et al. Pharmacokinetics of a new galenical formulation of oral cyclosporine A in stable kidney transplanted patients. Transplant Proc 1994; 26: 2969-72
28. Sketris LS, Lawen JG, Beauregard-Zollinger L, et al. Comparison of the pharmacokinetics of cyclosporine Sandimmune with Sandimmune neoral in stable renal transplant patients. Transplant Proc 1994; 26: 2961-3
29. Kovarik JM, Meuller EA, van Bree JB. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994; 16: 232-7
30. Kovarik J, Kallay Z, Mueller EA, et al. Acute effect of cyclosporin on renal function following the initial changeover to a microemulsion formulation of stable kidney transplant patients. Transplant Int 1995; 8: 335-9
31. Wahlberg J, Wilczek H, Fauchald P, et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 1995; 60: 648-52
32. Levy G, Rochon J, Freeman D, et al. Cyclosporine neoral liver transplant recipients. Transplant Proc 1994; 26: 2949-52
33. Mikhail G, Eadon H, Leaver N, et al. Use of neoral in heart transplant recipients. Transplant Proc 1994; 26: 2985-7
34. Fiocchi R, Mamprin A, Gamba M, et al. Pharmacokinetic profile of cyclosporine in long-term heart transplanted patients treated with a new oral formulation. Transplant Proc 1994; 26: 2994-5
35. Kovarik JM, Meuller EA, van Bree JB, et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83: 444-6
36. Keown PA, Stiller CR, Laupacis AL, et al. The effects and side effects of cyclosporine: relationship to drug pharmacokinetics. Transplant Proc 1982; 14: 659-61
37. Keown PA, Stiller CR, Sinclair NR, et al. The clinical relevance of cyclosporine concentrations as measured by radioimmunoassay. Transplant Proc 1983; 15: 2438-41
38. Ptachinski RJ, Venkataramanan R, Rosenthal JT. The effect of food on cyclosporine absorption. Transplantation 1985; 40: 174-6
39. Mueller EA, Kovarik JM, Kutz K. Minor influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine. Transplant Proc 1994; 26: 2957-8
40. Kovarik JM, Mueller EA, Johnston A, et al. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy 1993; 13: 613-7
41. Kovarik JM, Vaernillet L, Mueller EA, et al. Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemulsion formulation. Ther Drug Monit 1994: 16: 519-25
42. Taesch S, Niese D. Safety and tolerability of a new oral formulation of cyclosporine A, Sandimmun neoral, in renal transplant patients. Transplant Int 1994; 7 Suppl. 1: 263-6
43. Neumayer HH, Färber L, Haller P, et al. Conversion from Sandimmun to Sandiummun neoral in patients with stable renal allografts: results after 1 month. Transplant Proc 1994; 26: 2944-8
44. Belli LS, Slim OA, De Carlis L, et al. Neoral liver transplant patients: pharmacokinetic study and clinical implications. Transplant Proc 1994; 26: 2981-2
45. Atkison PR, Grant DR, Williams SE, et al. Sandimmune neoral in paediatric liver transplant recipients with malabsorption of cyclosporin A. Transplant Proc 1994; 26: 2953-4
46. Burckart GJ, Venkataramanan R, Ptachinski RJ, et al. Cyclosporine absorption following orthotopic liver transplantation. J Clin Pharmacol 1986; 26: 647-51
47. Färber L, Maibücher P, Geissler F, et al. Favourable clinical results of Sandimmun-neoral in malabsorbing liver and heart transplant recipients. Transplant Proc 1994; 26; 2988-93
48. Ferrera G, Fioredda P, Loy A, et al. Oral microemulsion formulation substitutes for intravenous cyclosporin in child with graft-versus-host disease. Lancet 1994; 344: 480-1
49. Ringden O, Bäckman L, Lönnqvist B, et al. A randomized trial comparing the use of cyclosporin and methotrexate for graft versus host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant 1986; 1: 41-51
50. Cockburn ITR, Krupp P. An appraisal of drug interactions with Sandimmun. Transplant Proc 1989; 21: 3845-50